Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
Titel:
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma
Auteur:
Rao, S. Watkins, D. Cunningham, D. Dunlop, D. Johnson, P. Selby, P. Hancock, B.W. Fegan, C. Culligan, D. Schey, S. Morris, T.C.M. Lissitchkov, T. Oliver, J.W. Holmlund, J.T.